Nektar Therapeutics

Last updated
Nektar Therapeutics
FormerlyInhale Therapeutic Systems, Inc.
Company type Public
Industry Biopharmaceuticals
Founded1990;35 years ago (1990)
Headquarters San Francisco, California, U.S.
Products
Revenue US$90.1million (2023) [1]
Number of employees
137 (2024)
Website nektar.com

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. [2] The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, [3] which improves drug characteristics like retention and solubility. [4] It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. [2] The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough. [5]

Contents

Background

The company is engaged in developing a proprietary pipeline of drug candidates for several therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. [2] The company's research and development involve in small molecule and biologic drug candidates. Its drug candidate base consists of naloxegol (Movantik), a Phase III oral opioid antagonist, etirinotecan pegol, a topoisomerase inhibitor under Phase III clinical study as of 2012, NKTR 061, NKTR-181, NKTR-214, etc. [6]

In 2013, the company was assigned a patent which was developed by the company and other four co-inventors. [7] The products of the company is served as a supplement to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability and other areas of drugs for the patients worldwide. [8] As of March 2014, the company had a market capitalization of $1.7 billion with an enterprise value of $1.67 billion. [1]

As of December 2024, at a stock price-per-share of roughly $1, the market cap is roughly $171 million. [9] Nektar underwent periods of downsizing after unsuccessful partnerships were ended with Eli Lilly in 2023 and Bristol Myers Squibb in 2022, resulting in layoffs of most company employees. [4]

Pipeline

Etirinotecan pegol was in the phase III BEACON trial as well as in the I-SPY2 adaptive clinical trial for breast cancer in 2016. [10] The European Medicines Agency refused a marketing authorisation in 2017. [11]

Bempegaldesleukin (NKTR-214) is a CD122-biased immune-stimulatory cytokine, [12] Phase I results were announced in November 2016. [13] It is now in a phase 2 trial in combination with nivolumab for various advanced cancers. [14]

In 2023 Nektar's partnership with Eli Lilly in development of "rezpeg" was ended. Eli Lilly claimed the drug lacked suitable efficacy, while Nektar responded that Eli Lilly had botched the analysis. [4]

References

  1. 1 2 "Nektar Therapeutics".
  2. 1 2 3 "BDR: Summary for Nektar Therapeutics, Inc.- Yahoo! Finance". Finance.yahoo.com. Retrieved 2014-03-17.
  3. ↑ "Nextar Therapeutics Inc. brief introduction NASDAQ". Nasdaq.com. Retrieved 2014-03-16.
  4. 1 2 3 Kansteiner, Fraiser (2024-11-04). "Nektar extends cash runway with $90M manufacturing plant sale". www.fiercepharma.com. Retrieved 2024-12-19.
  5. ↑ Totty, Michael (2006-09-11). "The Winners Are..." Wall Street Journal. ISSN   0099-9660 . Retrieved 2020-01-22.
  6. ↑ "NKTR reuter.com". Reuters.com. Archived from the original on 2014-03-16. Retrieved 2014-03-16.
  7. ↑ "Nektar Therapeutics : U.S. Patents Awarded to Inventors in Alabama (Feb. 8)". 4-traders.com. 2014-02-08. Retrieved 2014-03-16.
  8. ↑ "Nextar Marketwatch Quote Summary". Marketwatch.com. Retrieved 2014-03-16.
  9. ↑ "Nektar Therapeutics Market Cap 2010-2024 | NKTR". www.macrotrends.net. Retrieved 2024-12-19.
  10. ↑ Kuznar, Wayne (28 June 2016). "Novel Agents are Targeting Drivers of TNBC: Several drug candidates in I-SPY2 have 'graduated' to later-phase studies". Medpage Today. Retrieved 23 February 2024.
  11. ↑ "Onzeald". European Medicines Agency. 2017-11-10.
  12. ↑ "Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine". Nektar Therapeutics. June 2, 2015. Archived from the original on 19 December 2017. Retrieved 25 June 2015.
  13. ↑ Martins, Ines (17 November 2016). "Immunotherapy, NKTR-214, Shows Activity Against Solid Tumors in Study" . Retrieved 2020-11-12.
  14. ↑ Inman, Silas (12 November 2017). "NKTR-214/Nivolumab Combination Shows Promise in Early Study". OncLive. Retrieved 12 November 2020.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.